Cargando…

Induction therapy and outcome of proliferative lupus nephritis in the top end of Northern Australia – a single centre study retrospective study

BACKGROUND: Lupus nephritis is a common manifestation of Systemic Lupus Erythematosus. Mycophenolate is recommended by guidelines for induction therapy in patients with proliferative lupus nephritis and nephrotic range proteinuria Class V lupus nephritis. Indigenous Australians suffer disproportiona...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Chi, Goh, Kim Ling, Abeyaratne, Asanga, Priyadarshana, Kelum
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254616/ https://www.ncbi.nlm.nih.gov/pubmed/35787253 http://dx.doi.org/10.1186/s12882-022-02849-w

Ejemplares similares

Histopathology pattern and survival analysis of patients with kidney biopsy in the top end of Northern Australia from 2007 to 2020
por: Goh, Kim Ling, et al.
Publicado: (2022)

Exploring the appropriateness of prescribing practice of inhaled pharmacotherapy among Aboriginal Australians in the Top End Northern Territory of Australia: a retrospective cohort study
por: Heraganahally, Subash, et al.
Publicado: (2023)

Molecular characterization of proliferative lupus nephritis
por: Parikh, Samir V, et al.
Publicado: (2014)

Non-histologic factors discriminating proliferative lupus nephritis from membranous lupus nephritis
por: Kwon, Oh Chan, et al.
Publicado: (2020)

Development and validation of algorithms to identify patients with chronic kidney disease and related chronic diseases across the Northern Territory, Australia
por: Chen, Winnie, et al.
Publicado: (2022)

Differences and similarities of proliferative and non-proliferative forms of biopsy-proven lupus nephritis: Single centre, cross-disciplinary experience
por: Duran, Emine, et al.
Publicado: (2022)

Comparing the Efficacy and Safety of Induction Therapies for the Treatment of Patients with Proliferative Lupus Nephritis in South Africa
por: Sogayise, Phelisa, et al.
Publicado: (2020)

Rescue treatment of severe lupus myocarditis and proliferative lupus nephritis with immunoadsorption
por: Štambuk, Sandra Karanović, et al.
Publicado: (2023)

Contemporary estimates of the risk of end-stage renal disease in the first decade of proliferative lupus nephritis
por: Ward, MM, et al.
Publicado: (2012)

The outcome of proliferative lupus nephritis with pulse cyclophosphamide therapy
por: Annavarajula, S. K., et al.
Publicado: (2011)

Prevalence and clinical impact of magnesium disorders in end-stage renal disease: a protocol for a systematic review
por: Floridis, John, et al.
Publicado: (2015)

Comparison of Two Steroid Regimens in Induction Therapy of Proliferative Lupus Nephritis: A Randomized Controlled Trial
por: Bharati, Joyita, et al.
Publicado: (2019)

Identification of urinary metabolites that distinguish membranous lupus nephritis from proliferative lupus nephritis and focal segmental glomerulosclerosis
por: Romick-Rosendale, Lindsey E, et al.
Publicado: (2011)

A Predictive Model for Estimation Risk of Proliferative Lupus Nephritis
por: Chen, Dong-Ni, et al.
Publicado: (2018)

Anti-Myeloperoxidase Antibodies Associate with Future Proliferative Lupus Nephritis
por: Olson, S. W., et al.
Publicado: (2017)

Proliferative lupus nephritis in the absence of overt systemic lupus erythematosus: A historical study of 12 adult patients
por: Touzot, Maxime, et al.
Publicado: (2017)

Pilot study comparing the childhood arthritis and rheumatology research alliance consensus treatment plans for induction therapy of juvenile proliferative lupus nephritis
por: Cooper, Jennifer C, et al.
Publicado: (2018)

Clinicopathologic correlations of renal microthrombosis and inflammatory markers in proliferative lupus nephritis
por: Gonzalo, Elena, et al.
Publicado: (2012)

Differing environmental risk factors for membranous versus proliferative lupus nephritis
por: Dooley, MA, et al.
Publicado: (2012)

The Steroids In the Maintenance of remission of Proliferative Lupus nephritis (SIMPL) pilot trial
por: Galbraith, Lauren, et al.
Publicado: (2014)

Hydroxychloroquine in children with proliferative lupus nephritis: a randomized clinical trial
por: Gheet, Fatma Sayed, et al.
Publicado: (2023)

Long-term renal outcomes of patients with non-proliferative lupus nephritis
por: Kang, Eun-Song, et al.
Publicado: (2023)

A Randomized Controlled Trial Comparing Remission Induction with Modified Multitarget Therapy with Intravenous Cyclophosphamide in Proliferative Lupus Nephritis
por: Pal, Atanu, et al.
Publicado: (2023)

Developing consensus treatment plans for proliferative lupus nephritis in childhood-onset systemic lupus erythematous
por: Mina, Rina, et al.
Publicado: (2012)

Trends in Bacteremia Over 2 Decades in the Top End of the Northern Territory of Australia
por: Douglas, Nicholas M, et al.
Publicado: (2020)

Outcomes of membranous and proliferative lupus nephritis – analysis of a single-centre cohort with more than 30 years of follow-up
por: Farinha, Filipa, et al.
Publicado: (2020)

Sickle cell nephropathy with diffuse proliferative lupus nephritis: a case report
por: Kanodia, Kamal V, et al.
Publicado: (2008)

Interleukin (IL) 16: a candidate urinary biomarker for proliferative lupus nephritis
por: Häyry, Aliisa, et al.
Publicado: (2022)

Renal Tissue Expression of BAFF and BAFF Receptors Is Associated with Proliferative Lupus Nephritis
por: Marín-Rosales, Miguel, et al.
Publicado: (2022)

Treatment Outcomes of Proliferative vs. Non-proliferative Adult Lupus Nephritis: A 10-Year Follow-Up
por: Zahab, Mohamed, et al.
Publicado: (2021)

Mycophenolate mofetil as maintenance therapy for proliferative lupus nephritis: a long-term observational prospective study
por: Laskari, Katerina, et al.
Publicado: (2010)

Unexpected recovery from longterm renal failure in severe diffuse proliferative lupus nephritis
por: Ross, Sophia, et al.
Publicado: (2012)

Clinical features, epidemiology, and short-term outcomes of proliferative lupus nephritis in Eastern India
por: Sircar, D., et al.
Publicado: (2013)

The development of membranous lupus nephritis during treatment with mycophenolate mofetil for proliferative renal disease
por: Dalton, Kristen, et al.
Publicado: (2010)

Anti-DFS70 Antibodies Are Associated With Proliferative Lupus Nephritis and Renal Pathological Activity
por: Chen, Dandan, et al.
Publicado: (2022)

Discovery of NEU1 as a candidate renal biomarker for proliferative lupus nephritis chronicity
por: Mao, Zhaomin, et al.
Publicado: (2021)

Methodological quality of studies of end-stage renal disease risks in lupus nephritis
por: Tektonidou, Maria, et al.
Publicado: (2014)

Efficacy and safety of tacrolimus in induction therapy of patients with lupus nephritis
por: Zhou, Tianbiao, et al.
Publicado: (2019)

Rituximab alone as induction therapy for membranous lupus nephritis: A multicenter retrospective study
por: Chavarot, Nathalie, et al.
Publicado: (2017)

Iguratimod as an alternative induction therapy for refractory lupus nephritis: a preliminary investigational study
por: Kang, Yuening, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_aq3ak2tkloatues2ko8vc30p56